Samengesteld · Gezondheidszorg

Big pharma

Door InspectStocksPublished 14 okt 202613 companies0 followers

The largest drugmakers, selling prescription medicines worldwide.

Gegroepeerd met hulp van een AI-model en nagekeken door onze redactie. De regel onder elk bedrijf zegt waarom het hier staat.

Download image

Kaarten Niveaus

Aandelenkoersen zijn de slotkoersen van 11 nov 2026, uit de IEX-beursfeed.

Grade mix

A 7B 3C 3

Revenue growing

12 of 12

Free cash flow growing

9 of 13

Median price move, 1 year

+34,0%

Sort by

LLYELI LILLY AND COMPANY
Drug manufacturers generalMarket cap US$ 1,35TP/E 46,67
US$ 1.437,79+42,2%1Y
Since added +23,2%
A+
Groei en kasstroom
Groeit sterk
Business trend
Stabiel
Business quality
Sterk
Getting better
Verbetert
Revenue
US$ 86,5B+45,5%
Profit
US$ 27,6B+49,8%
Free cash flow
US$ 19,7B+112,1%
Discuss
Why it is here: Sells prescription medicines for diabetes, obesity, cancer and inflammation
JNJJohnson & Johnson
Drug manufacturers generalMarket cap US$ 674,9BP/E 42,54
US$ 280,34+47,5%1Y
Since added +12,8%
A+
Groei en kasstroom
Groeit sterk
Business trend
Stabiel
Business quality
Sterk
Getting better
Gemengd
Revenue
US$ 99,3B+7,8%
Profit
US$ 16,1B-35,9%
Free cash flow
US$ 20,6B+5,1%
Discuss
Why it is here: Sells prescription medicines for cancer and immune disorders
ABBVAbbVie Inc.
Drug manufacturers generalMarket cap US$ 521,2BP/E 50,75
US$ 294,87+30,2%1Y
Since added +7,5%
B+
Groei en kasstroom
Groeit sterk
Business trend
Stabiel
Business quality
Sterk
Getting better
Verbetert
Revenue
US$ 66B+10,7%
Profit
US$ 10,3B+333,1%
Free cash flow
US$ 18,9B-4,1%
Discuss
Why it is here: Sells medicines for immune, neurological and cancer conditions
MRKMerck & Co., Inc.
Drug manufacturers generalMarket cap US$ 362,9BP/E 150,20
US$ 147,20+65,7%1Y
Since added +3,7%
A
Groei en kasstroom
Groeit sterk
Business trend
Stabiel
Business quality
Solide
Getting better
Gemengd
Revenue
US$ 67,4B+4,9%
Profit
US$ 2,5B-87,1%
Free cash flow
US$ 14,7B+13,0%
Discuss
Why it is here: Sells prescription medicines and vaccines for people and animals
NVSNovartis AG
Drug manufacturers generalMarket cap US$ 306BGeen K/W (bedrijfsverlies)
US$ 160,36+23,6%1Y
Since added +12,6%
A
Groei en kasstroom
Groeit sterk
Business quality
Gemengd
Getting better
Verbetert sterk
Revenue
US$ 56,7B+9,6%
Profit
US$ -46MNo comparable year
Free cash flow
US$ 17,6B+8,3%
Discuss
Why it is here: Sells prescription medicines
AZNASTRAZENECA PLC
Drug manufacturers generalMarket cap US$ 289,7BP/E 28,36
US$ 185,49+115,2%1Y
Since added +19,0%
B+
Groei en kasstroom
Groeit sterk
Business trend
Vertragend
Business quality
Sterk
Getting better
Verbetert sterk
Revenue
US$ 62,4B+7,3%
Profit
US$ 10,2B+45,3%
Free cash flow
US$ 11,8B+18,4%
Discuss
Why it is here: Sells prescription medicines
NVONOVO NORDISK A/S
Drug manufacturers generalMarket cap US$ 182,8BP/E 11,84
US$ 41,10-15,4%1Y
Since added +8,0%
C+
Groei en kasstroom
Groeit
Business trend
Versnellend
Business quality
Sterk
Getting better
Verbetert
Revenue
US$ 50,3B+5,7%
Profit
US$ 17,1B+9,1%
Free cash flow
US$ 8,9B-20,1%
Discuss
Why it is here: Sells diabetes and obesity medicines
PFEPFIZER INC
Drug manufacturers generalMarket cap US$ 167,9BP/E 42,07
US$ 29,45+21,4%1Y
Since added +3,8%
C
Groei en kasstroom
Groeit sterk
Business trend
Krimpend
Business quality
Solide
Getting better
Gemengd
Revenue
US$ 63,6B+1,3%
Profit
US$ 4B-59,0%
Free cash flow
US$ 11,8B+13,6%
Discuss
Why it is here: Sells prescription medicines and vaccines
BMYBRISTOL-MYERS SQUIBB COMPANY
Drug manufacturers generalMarket cap US$ 128,6BP/E 13,95
US$ 62,92+34,0%1Y
Since added +11,0%
C+
Groei en kasstroom
Groeit
Business trend
Stabiel
Business quality
Sterk
Getting better
Verbetert sterk
Revenue
US$ 50B+4,2%
Profit
US$ 9,2B+53,1%
Free cash flow
US$ 9,3B-39,3%
Discuss
Why it is here: Sells prescription medicines for cancer and immune conditions
SNYSanofi
Drug manufacturers generalMarket cap US$ 59,1BP/E 6,81
US$ 48,43-3,0%1Y
Since added +23,9%
B
Groei en kasstroom
Groeit sterk
Business trend
Stabiel
Business quality
Gemengd
Getting better
Verbetert
Revenue
US$ 53,5B+11,6%
Profit
US$ 4,7B-54,2%
Free cash flow
US$ 8,1B+22,5%
Discuss
Why it is here: Sells prescription medicines and vaccines
GSKGSK plc
Drug manufacturers generalMarket cap US$ 109,2BP/E 13,60
US$ 50,60+8,9%1Y
Since added +9,3%
A+
Groei en kasstroom
Groeit sterk
Business quality
Sterk
Getting better
Verbetert sterk
Revenue
US$ 43,8B+4,1%
Profit
US$ 7,7B+122,0%
Free cash flow
US$ 8,6B+24,0%
Discuss
Why it is here: Sells prescription medicines and vaccines worldwide
AMGNAmgen Inc.
Drug manufacturers generalMarket cap US$ 253,2BP/E 27,14
US$ 468,13+43,1%1Y
Since added +13,4%
A+
Groei en kasstroom
Groeit sterk
Business trend
Stabiel
Business quality
Sterk
Getting better
Verbetert
Revenue
US$ 38,9B+8,2%
Profit
US$ 9,4B+34,1%
Free cash flow
US$ 9,6B-17,0%
Discuss
Why it is here: Develops and sells medicines and biosimilars for serious diseases
TAKTakeda Pharmaceutical Company Limited
Drug manufacturers specialty and genericMarket cap US$ 33,5BP/E 48,79
US$ 20,86+50,1%1Y
Since added +12,5%
A
Groei en kasstroom
Groeit sterk
Business quality
Gemengd
Getting better
Gemengd
Revenue
US$ 29,8BNo comparable year
Profit
US$ 259,4MNo comparable year
Free cash flow
US$ 5,5B+1,1%
Discuss
Why it is here: Sells prescription medicines and vaccines globally

Green and red compare each figure with the same window a year earlier. Grades and checks are the company page's own; nothing here is a recommendation.

DiscussionNo comments yet

Be civil and stick to the companies. Comments are opinions, not advice.

Lists are their owners' own, and notes and comments are opinions. Grades describe businesses from their filings; nothing here is a recommendation to buy or sell.